Key result
High-THC cannabis use is linked to increased cardiovascular risks, particularly in younger individuals.
Why the study?
Cannabis use has increased substantially over the past 2 decades, but the cardiovascular effects of cannabis exposure remain largely understudied.
Does cannabis use increase the risk of cardiovascular conditions (atherosclerosis, arrhythmias, heart failure, and stroke) in exposed individuals?
Systematic Review
Does cannabis use increase the risk of cardiovascular conditions (atherosclerosis, arrhythmias, heart failure, and stroke) in exposed individuals?
Acute and high Δ9-tetrahydrocannabinol/cannabidiol ratio cannabis use is associated with increased risks of cardiovascular conditions such as atherosclerosis, arrhythmias, heart failure, and stroke, warranting routine clinical assessment of cannabis exposure.
Answers are grounded in this paper and cite their sources.
Highlights need for caution with cannabis in CV-risk patients; leaves open the magnitude of effects pending prospective data.
Cannabis use has increased substantially over the past 2 decades following shifts in public perception, legalization, and medical usage. Although neurological and psychiatric effects are well known, the cardiovascular effects of cannabis exposure are largely understudied. This review evaluates the cardiovascular effects of cannabis use by examining clinical evidence, epidemiological data, and underlying biochemical mechanisms. This review examines cannabis‐related cardiovascular conditions, including atherosclerosis, arrhythmias, heart failure, and stroke. The analysis focused on cannabinoid composition, route of administration, frequency of use, and cardiovascular outcomes. Evidence indicates that acute and high Δ 9 ‐tetrahydrocannabinol/cannabidiol ratio cannabis use is associated with increased risks of various cardiovascular outcomes, especially among younger individuals without cardiovascular risk factors. Given rising use and increasing Δ 9 ‐tetrahydrocannabinol potency, clinicians must routinely assess cannabis exposure when evaluating cardiovascular disease, especially in younger patients. Future research must prioritize the development of standardized exposure metrics in cannabis‐related cardiovascular disease research, thus allowing clinicians and patients to better understand the cardiovascular risks of cannabis use and initiate effective cessation strategies.
No takes yet. Share an insight, caveat, or question.
Chehade et al. (2026) conducted a systematic review in Cardiovascular disease (including atherosclerosis, arrhythmias, heart failure, and stroke). Cannabis use (acute and high Δ9-tetrahydrocannabinol/cannabidiol ratio exposure) was evaluated on Cardiovascular outcomes (including atherosclerosis, arrhythmias, heart failure, and stroke). Acute and high Δ9-THC/cannabidiol ratio cannabis use is associated with increased risks of atherosclerosis, arrhythmias, heart failure, and stroke, particularly in younger individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: